Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Repare Therapeutics Inc. has received a consensus rating of "Hold" from five research firms, with an average twelve-month price target of $4.50.
• The company's stock recently traded down 2.2% to $1.80, with a market capitalization of approximately $77.33 million.
• Institutional investors own 85.09% of Repare Therapeutics shares, with several firms increasing their stakes significantly over the past few quarters.

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $4.50.

Several research firms recently issued reports on RPTX. Wall Street Zen upgraded Repare Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Repare Therapeutics in a research report on Saturday, September 27th.

Repare Therapeutics Trading Down 2.2%

Shares of RPTX stock traded down $0.04 on Friday, hitting $1.80. 157,138 shares of the stock were exchanged, compared to its average volume of 273,665. Repare Therapeutics has a one year low of $0.89 and a one year high of $4.07. The firm's 50 day moving average is $1.64 and its two-hundred day moving average is $1.42. The firm has a market capitalization of $77.33 million, a PE ratio of -0.70 and a beta of 1.08.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.17. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $2.50 million. On average, sell-side analysts expect that Repare Therapeutics will post -2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC raised its stake in Repare Therapeutics by 65.5% during the fourth quarter. Millennium Management LLC now owns 170,959 shares of the company's stock valued at $224,000 after buying an additional 67,638 shares during the last quarter. Affinity Asset Advisors LLC raised its stake in Repare Therapeutics by 100.0% during the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock valued at $197,000 after buying an additional 100,000 shares during the last quarter. Acadian Asset Management LLC raised its stake in Repare Therapeutics by 35.6% during the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock valued at $624,000 after buying an additional 168,230 shares during the last quarter. Rangeley Capital LLC purchased a new position in Repare Therapeutics during the second quarter valued at $494,000. Finally, Militia Capital Partners LP purchased a new position in Repare Therapeutics during the second quarter valued at $166,000. Hedge funds and other institutional investors own 85.09% of the company's stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.